Epigral Q4 FY26 results (Jan–Mar 2026) and concall

Chemicals · Concall AI · Call held 2 May 2026

Company page: Epigral share price, financials & guidance record

Epigral reported its highest ever quarterly revenue of INR 736 crores in Q4 FY26, driven by strong volume growth and normalized EBITDA margins of 23%. The company's capacity expansion projects for Epichlorohydrin and CPVC are on track, and it targets 10-12% volume growth for FY27. However, the West Asia conflict poses ongoing supply chain and raw material price volatility, and INR depreciation led to a significant increase in finance costs for FY26.

You’re reading a preview. Opening the full call uses 1 concall credit.

What they filed

Q4 FY26: revenue up 17.2%, net profit down 6.9% against the same quarter last year.

₹ Cr · quarterly

Line item	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26
Revenue	626	645	628	607	587 −6%	597 −7%	736 +17%
Expenses	448	463	454	443	455	494	569
EBITDA	178	183	173	163	132 −26%	103 −44%	168 −3%
Margin	28%	28%	28%	27%	22%	17%	23%
Other income	6	4	4	9	2	6	-1
Interest	27	0	12	23	22	11	16
Depreciation	32	33	34	42	42	43	42
Profit before tax	125	154	131	107	70 −44%	55 −64%	110 −16%
Tax rate	35%	33%	34%	-50%	26%	28%	26%
Net profit	81	104	87	161	51 −37%	39 −62%	81 −7%
EPS	19.57	24.02	20.14	37.25	11.87	9.07	18.76

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.

What they filed

More Chemicals earnings calls